skip to the content

Clinical Trials

Schizophrenia - Clinical Trial (08-296)

 Efficacy of Pimozide Augmentation for Clozapine Partial Response

Protocol ID

08-296

Protocol Description

The purpose of this project is to find out if small doses of pimozide (an antipsychotic medication, taken by mouth) will be helpful in reducing symptoms (such as hearing voices, having trouble in organizing one's thoughts, lack of interest in life events and social activities), compared to placebo, when given to patients with schizophrenia or schizoaffective disorder who are already taking clozapine.  Pimozide has been approved by the Food and Drug Administration (FDA) for the treatment of a movement disorder called Tourette syndrome.

Eligibility Criteria

Patients with schizophrenia or schizoaffective disorder who are already taking clozapine

North Shore University Hospital
300 Community Drive
Manhasset, NY 11030
Contact Information: (516) 562-0100

Primary Investigator(s)

  • Georgios Petrides, MD

Contact Information

Susan Ray, MS
(718) 470-8442
sray@lij.edu

Last Update

July 29, 2009
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Mental Health:
top
top